Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S5 - E17.5 - Previewing EASL Congress 2024: Focusing On MASLD Drug Development
Description: This final conversation from SurfingMASH's EASL Congress 2024 preview includes two final papers, one covering MASLD drug development, and a diverse set of answers to Roger Green's closing question. Jörn Schattenberg discusses a paper he will present on a completely new concept to treat MASLD, a Phase 2a trial of a transglutaminase inhibitor, a compound originally developed for Celiac disease. Aleksander Krag describes as "exciting" the idea that this concept came from Celiac disease. Michelle Long discusses a late-breaker abstract, which means it is embargoed, and she cannot share many details. This is another "really g...